Research programme: mRNA based antiviral vaccines and passive immunity therapeutics - Valera/Merck

Drug Profile

Research programme: mRNA based antiviral vaccines and passive immunity therapeutics - Valera/Merck

Alternative Names: mRNA 1566

Latest Information Update: 15 Jan 2016

Price : $50

At a glance

  • Originator Valera LLC
  • Developer Merck & Co; Valera LLC
  • Class RNA; Vaccines
  • Mechanism of Action Immunostimulants; Protein synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Viral infections

Most Recent Events

  • 11 Jan 2016 Merck in-licenses mRNA based vaccines from Moderna
  • 13 Jan 2015 Early research in Viral infections in USA (Parenteral)
  • 13 Jan 2015 Moderna Therapeutics, through its subsidiary Valera LLC and Merck & Co. agree to co-develop mRNA based vaccines and passive immunity therapeutics for Viral infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top